For US Healthcare Providers Only
Makena is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history
There may be some confusion in the healthcare community about the current status of Makena. At this time, it is important to know that Makena’s approval and product label remain unchanged. The product continues to remain available to patients and prescribers.
To learn more about current medical society guidelines, you can visit the American College of Obstetricians and Gynecologists and/or the Society for Maternal-Fetal Medicine website(s).
If you have any questions, we welcome you to contact AMAG Pharmaceuticals at 1-877-411-2510 or by emailing medinfoUS@covispharma.com.
AMAG Pharmaceuticals, Makena, Makena Care Connection, and the logo designs presented in this material are trademarks of Covis Pharma GmbH. All rights reserved. ©2022 Covis Pharma GmbH.